atopic dermatitis
Recently Published Documents





2022 ◽  
Vol 147 ◽  
pp. 112633
Chetna Hemrajani ◽  
Poonam Negi ◽  
Arun Parashar ◽  
Gaurav Gupta ◽  
Niraj Kumar Jha ◽  

Nanomaterials ◽  
2022 ◽  
Vol 12 (2) ◽  
pp. 275
Cíntia Almeida ◽  
Patrícia Filipe ◽  
Catarina Rosado ◽  
Catarina Pereira-Leite

The human epidermis has a characteristic lipidic composition in the stratum corneum, where ceramides play a crucial role in the skin barrier homeostasis and in water-holding capacity. Several skin diseases, such as atopic dermatitis and psoriasis, exhibit a dysfunction in the lipid barrier with altered ceramide levels and increased loss of transepidermal water. Glucocorticoids are normally employed in the therapeutical management of these pathologies. However, they have shown a poor safety profile and reduced treatment efficiency. The main objective of this review is to, within the framework of the limitations of the currently available therapeutical approaches, establish the relevance of nanocarriers as a safe and efficient delivery strategy for glucocorticoids and ceramides in the topical treatment of skin disorders with barrier impairment.

Inflammation ◽  
2022 ◽  
Mab P. Corrêa ◽  
Rebeca D. Correia-Silva ◽  
Gisela R. Silva Sasso ◽  
Solange C. G. P. D’Ávila ◽  
Karin V. Greco ◽  

2022 ◽  
Vol 8 (12) ◽  
pp. 412-415
Narayan Prasad Modi ◽  
Arun Kumar Dash

Background: Atopic dermatitis (AD), also known as eczema, is one of the most common skin disorders among children and adults, with a steep rise in diagnoses among children. Many studies have investigated the relationship between Vitamin D3 (Vit D3) and AD. Methods: A randomized controlled trial was conducted among 60 children at SCB Medical College, Cuttack from August 2014 to November 2016. Children were randomly assigned to an intervention group that received 60,000 IU of Vit. D3 every week for 6 weeks in addition to regular treatment for AD and a control group that received same treatment of AD except for Vit. D3. Both the groups were followed up at 4 weeks and 8 weeks. Results: In 60 cases of moderate to severe AD, 70% of the patients were male. About 81.7% of patients were from urban areas and 56.7% belonged to a middle socioeconomic class. In 76.6% of cases, family history of atopy was present. At baseline, mean SCORAD was 47.8±7.5 in the intervention group, and 49.2±10.3 in the control group. At baseline, serum Vitamin. D3 level (ng/ml) was 17.6±1.8 in intervention and 17.3±3.5 in control group. After Vitamin. D3 supplementation, the SCORAD improved to 12.8±5.1 (75% reduction) at 4 weeks, and 3.6±2.1 (92% reduction) at 8 weeks in the intervention group. In the control group, the mean SCORAD was 18.8±9.1 (61% reduction) at 4 weeks, and 7.3±4 (85% reduction) at 8 weeks. Discussion: The improvement of serum 25-hydroxy Vit. D3 was 134% and 366% in the intervention group compared to 78% and 121% in the observation group after 4 weeks and 8 weeks respectively. The p-values at both the time points were significant (<0.05) for the intervention group as compared to the control group. Conclusion: Short-term therapeutic supplementation of Vitamin. D3 in children with moderate to severe AD improves the clinical score. There is an inverse relationship between serum Vitamin. D3 level and severity of AD.

Zarqa Ali ◽  
Andrei Chiriac ◽  
Theis Bjerre‐Christensen ◽  
Ari Pall Isberg ◽  
Priyanka Dahiya ◽  

Sign in / Sign up

Export Citation Format

Share Document